PACIRA BIOSCIENCES, INC. Income Taxes Receivable, Current
PACIRA BIOSCIENCES, INC. (PCRX) had Income Taxes Receivable, Current of $8.40 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes
us-gaap:IncomeTaxesReceivable · last filed 2026-08-04
- 2026-06-30: Income Taxes Receivable, Current $8.40M.
- 2026-03-31: Income Taxes Receivable, Current $7.90M.
- 2025-12-31: Income Taxes Receivable, Current $8.20M.
- 2025-07-31: Income Taxes Receivable, Current $4.60M.
| Period end | Income Taxes Receivable, Current |
|---|---|
| 2026-06-30 | $8.40M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $7.90M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $8.20M 10-Q · filed 2026-08-04 |
| 2025-07-31 | $4.60M 10-Q · filed 2026-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |